Bio Pharma Dive
MARCH 24, 2021
A group of drug companies, including Novartis, Takeda and Roche's Genentech, have agreed to collaborate with Vineti to usher in new identification standards for complex medicines.
World of DTC Marketing
MARCH 22, 2021
SUMMARY: Television remains the most important medium for healthcare advertising , accounting for 54.7% of all spend in 2018, far higher than television’s 30.8% share of the advertising market as a whole. However, recent trends indicate that healthcare marketers are shifting more dollars to digital ads. The shift to digital advertising doesn’t make sense when pharma product websites don’t meet consumers’ needs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
MARCH 25, 2021
A survey by the Pistoia Alliance indicates most professionals believe the tech can accelerate R&D, but companies are stymied by a skills gap and data bias.
pharmaphorum
MARCH 23, 2021
“Gamification” – adding game-like elements into non-game or real-world settings – has become a popular concept in the pharmaceutical, healthcare, and event industries, especially as virtual engagement becomes more common during COVID-19. However, it is proving more than a mere buzzword. With diverse applications and approaches, it is quickly becoming a promising tool for patient adherence, chronic disease management, preventive medicine, rehabilitation, and paediatric care, as well as for medica
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Bio Pharma Dive
MARCH 23, 2021
A disappointing recommendation from outside data reviewers raises doubts about the DNA-targeting drug's benefits and puts pressure on Roche's partner, Ionis Pharmaceuticals.
World of DTC Marketing
MARCH 21, 2021
SUMMARY: The goal of business is to maximize profits for shareholder returns but when a company that serves the public good pays CEOs millions of dollars in compensation while having among the highest profit margins within ANY industry I would argue that something is dreadfully wrong. The U.S. pharmaceutical firms behind the approved coronavirus vaccines — Johnson & Johnson, Moderna, and Pfizer — have quietly touted plans to raise prices on coronavirus vaccines in the near future and to capi
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
MARCH 25, 2021
In the year since the UK went into its first lockdown to limit the spread of COVID-19 the country’s health service has undergone an unprecedented digital transformation. . The NHS quickly scrambled to reduce face-to-face contact between patients and healthcare professionals, and manage demand for services that would soon be overstretched by dealing with the pandemic.
Bio Pharma Dive
MARCH 25, 2021
When given together with Opdivo, Bristol Myers' new drug kept skin cancers from progressing, a rare clinical victory for a combination of immunotherapies that puts the pharma a step ahead of several rivals.
World of DTC Marketing
MARCH 26, 2021
QUICK READ: If you start to lose key people, you won’t be able to keep the business you do have, and things will go from bad to worse. Companies who see their good employees as “replaceable” are wrong. Good employees are not replaceable. Pharma cannot afford to let good people leave without so much as an exit interview to try and retain them. A colleague recently decided to leave her organization to join another pharma company.
Pharma Times
MARCH 26, 2021
New initiative aims to help researchers translate their ideas into innovations for cancer patients
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Camargo
MARCH 25, 2021
The Camargo Blog is publishing a four-part blog series highlighting those designation programs available specifically for products with rare disease indications : Orphan Drug Designation (ODD), Rare Pediatric Disease Designation (RPDD), and Humanitarian Use Device (HUD) designation. Subscribe to our mailing list at the bottom of this page to be notified when future installments are published.
Bio Pharma Dive
MARCH 26, 2021
In a Thursday meeting, advisers to the Food and Drug Administration concluded the companies didn't have a strong enough plan to mitigate the risks associated with tanezumab.
Pharma Mirror
MARCH 26, 2021
One of the best gifts you can give to another person is a beautiful smile. Though it costs you nothing, it goes a long way in adding to others and you. It typically has a favourable effect on others, attracts people to you, and makes you approachable and likeable. A smile is very important. It is a part of your dressing and personality. Without a smile, you are incomplete, no matter how expensively and gorgeously dressed you are.
Pharma Times
MARCH 22, 2021
Recurrent pericarditis is an autoinflammatory cardiovascular disease
pharmaphorum
MARCH 23, 2021
Novartis’ radioligand therapy Lu-PSMA-617 has met its target in prostate cancer, as its $2.1 billion acquisition of specialist pharma Endocyte looks to have been justified. . The big Swiss pharma added this drug to its pipeline after it swooped for Endocyte and so far it looks like a good piece of business, with potential blockbuster sales predicted for the drug if it makes it to market.
Bio Pharma Dive
MARCH 25, 2021
Updated results show the vaccine is only slightly less effective than AstraZeneca originally reported. But an unusual break with a study committee may damage perception of the shot.
Pharma Mirror
MARCH 23, 2021
The Japanese pharmaceutical market is preparing for renewed international growth and partnering. In response, CPhI Japan has opened a two-month long virtual event to meet demand from international pharma. Informa introduced CPhI Japan Connect – a new virtual platform for global professionals looking to grow pharma business in Japan – specifically to help its international audiences continue conversations, identify leads, and build new partnerships while international travel remains restricted.
Pharma Times
MARCH 26, 2021
Marketing authorisation application is seeking approval for advanced urothelial cancer
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
pharmaphorum
MARCH 22, 2021
For the past year, life science companies around the world worked at breakneck speed to develop and manufacture safe and effective treatments to respond to the COVID-19 pandemic. The scramble to produce vaccines and therapeutics and the challenges of getting these products to poorer countries underscores the growing importance of local pharma manufacturers for these emerging markets. .
Bio Pharma Dive
MARCH 25, 2021
Treatments from Lilly and Regeneron that combine two different antibodies should be used instead, according to health officials.
NY Times
MARCH 22, 2021
The company is preparing to apply for emergency authorization from the Food and Drug Administration. But the shot may not be needed in the United States.
Pharma Times
MARCH 25, 2021
Lead ‘Allosteric PLK1’ asset will initially target brain cancer
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
pharmaphorum
MARCH 24, 2021
Pfizer has begun clinical development of an antiviral pill against COVID-19, which could be prescribed to patients at the first sign of infection. The company was the first to get a vaccine approved against the disease with BioNTech and is now aiming to make a pill that could prevent it escalating once patients are infected. Being able to manage coronavirus infections and prevent hospitalisations and death would have huge benefits for wider society as well as patients after more than a year of l
Bio Pharma Dive
MARCH 22, 2021
New results could make Tecentriq the first immunotherapy available in the post-surgery setting, adding pressure on Merck & Co.'s Keytruda to succeed as well.
NY Times
MARCH 24, 2021
The company has been at loggerheads with the bloc over vaccine supply shortages and faces stringent export restrictions.
Pharma Times
MARCH 25, 2021
Study compared women who continued on relugolix combination therapy with women who discontinued treatment
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
MARCH 22, 2021
AstraZeneca is mourning the loss of one of its top scientists after eminent cancer researcher José Baselga passed away at the age of just 61. . Baselga was a heavyweight in oncology research, pursuing a career that saw him serve as physician-in-chief at Memorial Sloan Kettering Cancer Centre in the US and also hold the position as president of the American Association of Cancer Research (AACR) before joining AZ to lead the drugmaker’s cancer R&D in January 2019.
Bio Pharma Dive
MARCH 24, 2021
Slaoui was fired as board chair of Galvani Bioelectronics following an investigation by the company's majority shareholder GlaxoSmithKline, which said the claims were substantiated.
BioPharma Reporter
MARCH 22, 2021
Australiaâs Therapeutic Goods Administration (TGA) has approved manufacture of the AstraZeneca COVID-19 vaccine by CSL â Seqirus: reducing the country's dependence on limited supply from abroad and allowing a wider vaccination campaign to begin.
Pharma Times
MARCH 24, 2021
Report outlines two cases for using synthetic data in the clinical trial process
Expert insights. Personalized for you.
358 
Let's personalize your content